Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

TBF outperformed BUFLU in 5-year survival of AML patients

Key clinical point: Thiotepa, busulfan, and fludarabine (TBF) showed improved survival vs. busulfan and fludarabine (BUFLU).

Major finding: The 5-year actuarial survival was 51% for BUFLU and 68% for TBF (P = .002).

Study details: Retrospective comparison of 2 myeloablative conditioning regimens in 454 acute myeloid leukemia patients in remission.

Disclosures: This study was funded by AIRC, FARITMO, and ImmStuarta. The authors reported that they had conflicts of interest.